ASIAMONEY BROKERS POLL - 2022 Emkay Research (VOTE HERE)

Bandhan Bank

India Equity Research | BFSI - Banks July 23, 2022 **Result Update**



Refer to important disclosures at the end of this report

Lower LLP leads to earnings beat; stress pool swells due to Assam floods

- Bandhan reported a beat on PAT at Rs8.8bn (est.: Rs6.5bn), thanks to lower provisions, partly offset by lower treasury gains and PSLC fees due to the declassification of select agri loans as PSL. However, the overall GNPA ratio rose 79bps qoq to 7.3%, and SMA pool was up by 600bps to 12.7%, mainly due to moratorium exit in the RSA pool and Assam floods.
- Overall AUM was up 20% yoy/down 3% qoq, mainly dragged down by MFI. However, on the positive side, mortgage growth has seen an acceleration. As per management, MFI growth should re-accelerate as the impact of regulatory changes and the Assam floods recedes. Despite a rising CoF, the bank expects NIMs to be stable in FY23, but structurally they should trend down due to the rising share of secured loans (incl. mortgages).
- Overall EEB stress pool has inched slightly to Rs121bn (20% of MFI loans/12% of overall loans), but the bank expects a strong recovery in H2 (CGFMU recovery of Rs25bn and flow of funds from the government's Assam loan relief scheme) and a gradual normalization of Assam SMA pool by Dec'22.
- We trim our FY23-25 earnings estimates by 2-4%, mainly factoring in lower PSLC fees and high opex as the bank accelerates its investments in franchisee/people & tech. Retain Hold with an unchanged TP of Rs325 (2.2x Jun'24E ABV), given the bank's liability profile, capital buffers and expected improvement in RoEs, while remaining watchful of the stress movement in the Assam pool.

MFI portfolio decelerates, but mortgage growth accelerates: Bandhan reported sub-par credit growth due to slower disbursements (Rs54bn vs. Rs134bn), mainly in the MFI business. This was largely due to compliance with regulatory requirements in an otherwise seasonally weak quarter and some impact from the Assam floods. The bank expects MFI growth to improve with the heavy-lifting to be done in H2, by when the impact of Assam floods should also be moderated. On the other hand, mortgage growth has picked-up from the erstwhile Gruh franchise, armed with better pricing on the back of the bank's advantageous CoF. The bank remains determinant to grow the non-MFI book at a faster pace, while also growing the secured asset book. Although this could have some structural impact on margins in the long run, it could reduce asset-quality volatility in the MFI portfolio.

Asset quality takes a hit due to Assam floods and flow from restructured pool: Gross slippages remain elevated at Rs11bn/6% of loans, which were mainly from the MFI restructured pool. This, coupled with the seasonally slow recoveries/upgrades, led to a jump in the GNPA ratio by 79bps qoq to 7.2%. The MFI book's collection efficiency slipped to 94% in Q1 from 97% in Q4, mainly due to the Assam floods. The restructured pool has moderated to Rs58bn/6% of loans from Rs62bn/6.2% of loans due to the end of the moratorium; 43% of the borrowers are non-paying, and hence the incremental focus will be on normalizing the recoveries as the book comes out of the moratorium. The MFI stress pool inched up marginally to Rs121bn (20% of MFI loans/12% of overall loans), but the bank expects a robust recovery in H2 (CGFMU recovery of Rs25bn and flow of funds from the government's Assam loan relief scheme).

Outlook and valuations: Factoring in lower PSLC fees and high opex due to the accelerating investments in its franchisee/people & tech, we trim our FY23-25 earnings estimates by 2-4%. Retain Hold with an unchanged TP of Rs325, based on 2.2x Jun'24E ABV, given the bank's liability profile, capital buffers and expected improvement in RoEs, while remaining watchful of the stress movement in the Assam pool. Key risks: Prolonged asset-quality impact of Assam floods & delay in recovery from the Assam loan relief scheme.

Please see our sector model portfolio (Emkay Alpha Portfolio): BFSI-Banks (Page 8)

Financial Snapshot (Standalone)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Net income	95,856	1,15,379	1,17,909	1,40,303	1,72,463
Net profit	22,055	1,268	28,928	43,283	59,764
EPS (Rs)	13.7	0.8	18.0	26.9	37.1
ABV (Rs)	94.8	100.6	118.9	143.8	177.4
RoA (%)	2.1	0.1	1.9	2.4	2.7
RoE (%)	13.5	0.7	15.5	19.7	22.4
PE (x)	20.9	363.2	15.9	10.6	7.7
PABV report is intend	ded for tean ^{3.0} mka	av@whitemarg	uesolutio <mark>2,4</mark> .con	n use an d d owr	nloaded at 6

СМР	Target Price
Rs 286 as of (July 22, 2022)	Rs 325 (∎) 12 months
Rating	Upside
HOLD (∎)	13.6 %

Change in Estimates

EPS Chg FY23E/FY24E	E (%)	(2.3)/(2.9)
Target Price change (%)	-
Target Period (Months)		12
Previous Reco		HOLD
Emkay vs Consensus		
EPS Estim	nates	
	FY23E	FY24E
Emkay	18.0	26.9
Consensus	27.8	35.3
Mean Consensus TP (1	2M)	Rs 382
Stock Details		
Bloomberg Code	BA	NDHAN IN
Face Value (Rs)		10
Shares outstanding (mn)	1,611
52 Week H/L		350 / 230
M Cap (Rs bn/USD bn)		461 / 5.77
Daily Avg Volume (nos.))	73,06,347
Daily Avg Turnover (US	\$ mn)	28.2
Shareholding Pattern	Jun '22	
Promoters		40.0%

Promoters	40.0%
FIIs	35.6%
DIIs	7.1%
Public and Others	17.3%

Price Performance

(%)	1M	3M	6M	12M
Absolute	2	(13)	(3)	(6)
Rel. to Nifty	(6)	(11)	2	(11)

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Heet Khimawat

heet.khimawat@emkayglobal.com +91 22 6612 1275

Dixit Sankharva

dixit.sankharva@emkayglobal.com +91 22 6612 1281

Soumya Jain

soumya.jain@emkayglobal.com

Source: Company. Emkay Research
Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited
Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

2QFY22 **3QFY22**

CASA (%) - RHS

IQFY22


4QFY21

3QFY21

IQFY23


Story in Charts

Exhibit 1: Deceleration in MFI book led to gog decline




Source: Company, Emkay Research

Exhibit 3: The bank looks to gradually diversify away from group **MFI** business




Source: Company, Emkay Research

Exhibit 5: Higher slippages coupled with slow recoveries led to increase in GNPA ratio by 79bps



Source: Company, Emkay Research

Exhibit 7: We expect return ratios to improve to by FY25E



Source: Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 07/25/2022 11:36 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


1200 50 43 1000 40 800 30 600 93 20 400 10 200 0 Λ 4QFY22

Exhibit 2: CASA ratio remains healthy at 43%

Source: Company, Emkay Research


2QFY20 3QFY20 4QFY20

QFY20




IQFY21 2QFY21

Deposits(Rs bn)



Source: Company, Emkay Research

Exhibit 6: Overall collection efficiency deteriorated due to Assam floods



Source: Company, Emkay Research

Exhibit 8: The stock currently trades at 2.6x one-year forward ABV, largely factoring in recent impact of Assam floods



Exhibit 9: Actual vs. Estimates (Q1FY23)

Rs mn	Actual	Esti	mates	% Variation		Comments
		Emkay	Consensus	Emkay Consensus		
Net income	28,441	29,754	31,831	-4%	-11%	Lower other income led to a miss
PPOP	18,206	20,161	22,238	-10%	-18%	Higher staff expenses resulted in a miss
PAT	8,865	6,509	10,532	36%	-16%	Lower-than-expected LLPs led to a beat

Source: Company, Emkay Research

Exhibit 10: Quarterly Summary

(Rs mn)	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	YoY (%)	QoQ (%)	FY22	FY23E	YoY (%)
Interest Earned	34,100	31,809	34,087	38,716	40,554	19	5	1,38,711	1,69,462	22
Interest Exp	12,959	12,455	12,840	13,317	15,409	19	16	51,571	68,847	33
Net Interest Income	21,141	19,354	21,247	25,398	25,144	19	-1	87,140	1,00,616	15
Global NIMs (reported)	8.50	7.60	7.40	8.70	8.00	-50bps	-70bps	7.03	7.01	-2bps
Non-interest Income	6,169	4,916	7,123	9,644	3,297	-47	-66	28,239	17,294	-39
Operating Expenses	7,739	8,778	8,868	9,829	10,235	32	4	35,234	43,006	22
Pre Provisioning Profit	19,571	15,492	19,501	25,214	18,206	-7	-28	80,144	74,903	-7
Provision & Contingencies	14,609	55,779	8,057	47	6,424	-56	13,517	78,848	36,229	-54
РВТ	4,962	-40,287	11,444	25,167	11,782	137	-53	1,297	38,674	2,883
Income Tax Expense (Gain)	1,231	-10,201	2,855	6,143	2,917	137	-53	28	9,746	34,348
Net Profit/(Loss)	3,731	-30,086	8,590	19,023	8,865	138	121	1,268	28,928	2,181
Gross NPA (%)	8.18	10.82	10.81	6.46	7.25	-93bps	79bps	6.46	4.12	-234bps
Net NPA (%)	3.29	3.04	3.01	1.66	1.92	-137bps	26bps	1.66	1.06	-60bps
Deposits (Rs in bn)	773	819	845	963	931	20	-3	963	1,190	24
Net Advances (Rs in bn)	748	745	803	940	909	22	-3	940	1,118	19
Source: Company, Emkay Research										

Exhibit 11: Revision in Estimates

Y/E Mar (Rs mn)		FY23E			FY24E			FY25E	
	Earlier	Revised	% change	Earlier	Revised	% change	Earlier	Revised	% change
Net income	1,27,630	1,17,909	-7.6%	1,47,635	1,40,303	-5.0%	1,77,415	1,72,463	-2.8%
PPOP	85,847	74,903	-12.7%	97,939	89,614	-8.5%	1,18,135	1,12,000	-5.2%
PAT	29,608	28,928	-2.3%	44,569	43,283	-2.9%	62,528	59,764	-4.4%
EPS (Rs)	18.4	18.0	-2.3%	27.7	26.9	-2.9%	38.8	37.1	-4.4%
BV (Rs)	124.8	124.4	-0.3%	136.9	148.6	8.6%	184.7	182.0	-1.4%

Source: Emkay Research

Exhibit 12: Key assumptions

	FY22A	FY23E	FY24E	FY25E
Loan Growth %	14.1	21.0	23.0	24.5
Deposit Growth %	23.5	23.5	26.3	26.4
NIM %	7.0	7.0	7.0	6.9
GNPA %	6.5	4.1	2.9	2.2
Credit Cost %	8.6	3.4	2.5	2.0

Source: Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 07/25/2022 11:36 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 13: Key ratios and trends

	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23
Loans (Rs mn)	7,43,310	7,66,146	8,02,550	8,70,400	8,03,569	8,16,600	8,80,000	9,93,400	9,66,500
growth YoY %	17.7	19.4	22.6	21.1	8.1	6.6	9.7	14.1	20.3
Loans QoQ %	3.5	3.1	4.8	8.5	(7.7)	1.6	7.8	12.9	(2.7)
Composition %									
Micro- Banking assets	63.9	65.0	66.1	67.0	66.2	66.2	65.4	62.8	60.1
Non - Micro banking assets	36.1	35.0	33.9	33.0	33.8	33.8	34.6	37.2	39.9
Liability Profile									
Deposits (Rs mn)	6,06,100	6,61,277	7,11,880	7,79,722	7,73,336	8,18,983	8,44,998	9,63,306	9,30,570
growth YoY %	34.1	34.4	29.6	36.6	27.6	23.8	18.7	23.5	20.3
growth QoQ %	6.2	9.1	7.7	9.5	(0.8)	5.9	3.2	14.0	(3.4)
CASA %	37.1	38.2	42.9	43.4	42.9	44.6	45.6	41.6	43.2
CA %	4.9	5.0	4.9	5.9	4.5	4.4	4.6	5.7	4.7
SA %	32.1	33.3	38.0	37.5	38.4	40.3	41.0	35.9	38.5
Asset Quality (Rs mn)									
Gross NPA	10,067	8,740	8,592	57,578	64,404	87,636	94,416	63,800	69,675
GNPA %	1.43	1.18	1.11	6.80	8.18	10.82	10.81	6.46	7.25
NPA	3,358	2,625	2,013	28,610	24,579	22,658	24,131	15,642	17,491
NNPA %	0.48	0.36	0.26	3.51	3.29	3.04	3.01	1.66	1.92
PCR % - Specific	66.6	70.0	76.6	50.3	61.8	74.1	74.4	75.5	77.0
Capital Adequacy									
CAR %	26.5	25.7	26.2	23.5	24.8	20.4	20.0	20.1	19.4
Tier I %	23.2	22.2	21.4	22.5	23.8	19.4	19.0	18.9	18.3
ROA	2.3	3.6	2.4	0.4	1.3	(2.6)	2.8	6.0	2.5
ROE	14.1	22.5	14.6	2.4	8.5	(17.3)	22.2	46.5	19.7

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 07/25/2022 11:36 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Net interest income	75,634	87,140	1,00,616	1,19,357	1,45,823
Other income	20,223	28,239	17,294	20,946	26,640
Fee income	8,397	11,776	13,896	16,675	20,010
Net income	95,856	1,15,379	1,17,909	1,40,303	1,72,463
Operating expenses	28,169	35,234	43,006	50,689	60,463
Pre provision profit	67,687	80,144	74,903	89,614	1,12,000
PPP excl treasury	64,600	77,824	75,367	89,985	1,10,886
Provisions	38,201	78,848	36,229	31,749	32,102
Profit before tax	29,487	1,297	38,674	57,865	79,899
Тах	7,432	28	9,746	14,582	20,134
Tax rate	25	2	25	25	25
Profit after tax	22,055	1,268	28,928	43,283	59,764

Balance Sheet

Y/E Year End (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity	16,106	16,108	16,110	16,110	16,110
Reserves	1,57,976	1,57,704	1,84,318	2,23,273	2,77,060
Net worth	1,74,082	1,73,812	2,00,428	2,39,383	2,93,170
Deposits	7,79,722	9,63,306	11,89,883	15,02,779	18,98,999
Borrowings	1,68,004	1,99,212	1,80,286	1,63,586	1,48,673
Total liabilities	11,50,162	13,88,665	16,22,599	19,66,721	24,11,433
Cash and bank	33,354	49,426	59,311	71,173	85,408
Investments	2,51,554	2,90,787	3,31,308	3,87,839	4,62,648
Loans	8,16,129	9,39,749	11,18,254	13,88,316	17,37,434
Others	15,329	59,037	65,284	68,308	71,927
Total assets	11,50,162	13,88,665	16,22,599	19,66,721	24,11,433

Key Ratios (%)

· , · · · · · (· · ·)					
Y/E Year End	FY21	FY22	FY23E	FY24E	FY25E
NIM	7.6	7.2	7.1	7.0	6.9
Non-II/avg assets	2.0	2.2	1.1	1.2	1.2
Fee income/avg assets	0.8	0.9	0.9	0.9	0.9
Opex/avg assets	2.7	2.8	2.9	2.8	2.8
Provisions/avg assets	3.7	6.2	2.4	1.8	1.5
PBT/avg assets	2.9	0.1	2.6	3.2	3.6
Tax/avg assets	0.7	0.0	0.6	0.8	0.9
RoA	2.1	0.1	1.9	2.4	2.7
RoAE	13.5	0.7	15.5	19.7	22.4
GNPA (%)	6.8	6.5	4.1	2.9	2.2
NNPA (%)	3.5	1.7	1.1	0.7	0.6
Per Share Data (Rs)	FY21	FY22	FY23E	FY24E	FY25E
EPS	13.7	0.8	18.0	26.9	37.1
BVPS	108.1	107.9	124.4	148.6	182.0
ABVPS	94.8	100.6	118.9	143.8	177.4
DPS	0.0	0.0	1.4	2.7	3.7
Valuations (x)	FY21	FY22	FY23E	FY24E	FY25E
PER	20.9	363.2	15.9	10.6	7.7
P/BV	3.0	2.8	2.4	2.0	1.6
P/ABV	3.0	2.8	2.4	2.0	1.6
P/PPOP	6.8	5.8	6.2	5.1	4.1
Dividend Yield (%)	0.0	0.0	0.5	0.9	1.3

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

India Equity Research | Result Update

Growth (%)	FY21	FY22	FY23E	FY24E	FY25E
NII	19.6	15.2	15.5	18.6	22.2
PPOP	24.3	18.4	(6.5)	19.6	25.0
PAT	(27.1)	(94.2)	2,181.0	49.6	38.1
Loans	22.5	15.1	19.0	24.2	25.1

Quarterly (Rs mn)	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23
NII	21,141	19,354	21,247	25,398	25,144
NIM(%)	8.5	7.6	7.4	8.7	8.0
PPOP	19,571	15,492	19,501	25,214	18,206
PAT	3,731	(30,086)	8,590	19,023	8,865
EPS (Rs)	2.32	(18.68)	5.33	11.81	5.50
Source: Company, Emkay Research					
Shareholding Pattern (%)	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22
Promoters	40.0	40.0	40.0	40.0	40.0
FIIs	35.4	33.6	34.6	34.3	35.6
DIIs	2.0	2.5	1.9	4.6	7.1
Public and Others	22.6	23.9	23.5	21.1	17.3
Source: Capitaline					

Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
15-May-22	317	325	12m	Hold	Anand Dama
23-Jan-22	296	250	12m	Sell	Anand Dama
31-Oct-21	291	250	12m	Sell	Anand Dama
31-Jul-21	291	410	12m	Buy	Anand Dama
16-Jul-21	309	390	12m	Buy	Anand Dama
09-May-21	297	390	12m	Buy	Anand Dama
13-Apr-21	332	500	12m	Buy	Anand Dama
22-Jan-21	314	500	12m	Buy	Anand Dama
20-Jan-21	360	500	12m	Buy	Anand Dama
06-Jan-21	396	425	12m	Buy	Anand Dama
03-Nov-20	308	425	12m	Buy	Anand Dama
07-Oct-20	315	390	12m	Buy	Anand Dama
26-Sep-20	265	390	12m	Buy	Anand Dama
16-Jul-20	343	390	12m	Hold	Anand Dama
13-May-20	252	255	12m	Hold	Anand Dama
11-Apr-20	192	262	12m	Buy	Anand Dama
05-Apr-20	182	262	12m	Buy	Anand Dama
14-Jan-20	519	650	12m	Buy	Anand Dama
24-Oct-19	571	675	12m	Buy	Anand Dama
09-Oct-19	481	625	12m	Buy	Anand Dama
23-Sep-19	527	625	12m	Buy	Anand Dama
13-Sep-19	455	600	12m	Buy	Anand Dama

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 07/25/2022 11:36 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Emkay Alpha Portfolio – BFSI-Banks

EAP sector portfolio



Analyst: Anand Dama

Contact Details

anand.dama@emkayglobal.com +91 22 6624 2480

Sector

Banks

Analyst bio

Anand Dama is a CA, CPM (ICFAI) with total 13 years of research experience, in addition to 3 years in the finance/rating industry. His team currently covers 21 banks and 15 stocks in the NBFC/Insurance space.

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight based on Current NAV	vs last
BFSI-Banks	19.91	19.86	-0.2%	-5	100.00	
Axis Bank	1.98	1.97	0%	-1	9.90	0
AU Small Finance Bank	0.27	0.24	-9%	-3	1.22	
Bandhan Bank	0.20	0.20	1%	0	0.99	0
Bank of Baroda	0.21	0.20	-7%	-1	1.00	0
Canara Bank	0.13	0.11	-12%	-2	0.56	0
City Union Bank	0.00	0.04	NA	4	0.20	0
DCB Bank	0.00	0.00	NA	0	0.00	0
Equitas Small Finance Bank	0.00	0.00	NA	0	0.00	0
Federal Bank	0.22	0.20	-8%	-2	1.00	0
HDFC Bank	6.14	6.57	7%	43	33.00	0
ICICI Bank	5.58	5.52	-1%	-6	27.74	0
Indian Bank	0.00	0.00	NA	0	0.00	0
Indusind Bank	0.54	0.60	11%	6	3.03	0
Karur Vysya Bank	0.00	0.06	NA	6	0.32	0
Kotak Mahindra Bank	2.45	2.07	-16%	-38	10.40	0
Punjab National Bank	0.10	0.00	-100%	-10	0.00	0
RBL Bank	0.00	0.00	NA	0	0.00	0
State Bank of India	2.00	2.07	3%	7	10.40	0
Ujjivan Small Finance Bank	0.00	0.00	NA	0	0.00	0
Union Bank of India	0.04	0.00	-100%	-4	0.00	0
Yes Bank	0.05	0.00	-100%	-5	0.00	0
Cash	0.00	0.05	NA	5	0.24	0

Source: Emkay Research

High Conviction/Strong Over Weight

Sector portfolio NAV


	Base					Latest
	1-Apr-19	20-Jul-21	20-Jan-22	21-Apr-22	21-Jun-22	21-Jul-22
EAP - BFSI-Banks	100.0	117.6	130.3	125.7	114.4	124.4
BSE200 Neutral Weighted Portfolio (ETF)	100.0	115.1	127.7	123.2	112.2	121.8
*Performance measurement base date 1 st April 2019						

Source: Emkay Research

Price Performance (%)

	1m	3m	6m	12m
EAP - BFSI-Banks	8.7%	-1.0%	-4.5%	5.8%
BSE200 Neutral Weighted Portfolio (ETF)	8.6%	-1.1%	-4.6%	5.9%
Source: Emkay Research				

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%
SELL	Below -5%

Completed Date: 23 Jul 2022 02:30:54 (SGT) Dissemination Date: 23 Jul 2022 02:31:54 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of July 23, 2022
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of July 23, 2022.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 23, 2022
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the July 23, 2022

RESTRICTIONS ON I	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 07/25/2022 11:36 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.